SEOM SOGUG clinical guideline for treatment of kidney cancer (2022)

• Published in: Clinical & translational oncology 2023-09, Vol.25 (9), p.2732-2748
• Main Authors: Méndez-Vidal, María José, Lázaro Quintela, Martin, Lainez-Milagro, Nuria, Perez-Valderrama, Begoña, Suárez Rodriguez, Cristina, Arranz Arija, José Ángel, Peláez Fernández, Ignacio, Gallardo Díaz, Enrique, Lambea Sorrosal, Julio, González-del-Alba, Aránzazu
• Format: Article
• Language: English
• Subjects: Carcinoma, Renal Cell - drug therapy; Carcinoma, Renal Cell - therapy; Clinical Guides in Oncology; Female; Humans; Kidney Neoplasms - drug therapy; Kidney Neoplasms - therapy; Male; Medicine; Medicine & Public Health; Nivolumab - therapeutic use; Oncology; Quality of Life; Sunitinib - adverse effects; Tyrosine - therapeutic use
• ISSN: 1699-3055; 1699-048X; 1699-3055
• DOI: 10.1007/s12094-023-03276-5

Renal cancer is the seventh most common cancer in men and the tenth in women. The aim of this article is to review the diagnosis, treatment, and follow-up of renal carcinoma accompanied by recommendations with new evidence and treatment algorithms. A new pathologic classification of RCC by the World Health Organization (WHO) was published in 2022 and this classification would be considered a “bridge” to a future molecular classification. For patients with localized disease, surgery is the treatment of choice with nephron-sparing surgery recommended when feasible. Adjuvant treatment with pembrolizumab is an option for intermediate-or high-risk cases, as well as patients after complete resection of metastatic disease. More data are needed in the future, including positive overall survival data. Clinical prognostic classification, preferably IMDC, should be used for treatment decision making in mRCC. Cytoreductive nephrectomy should not be deemed mandatory in individuals with intermediate-poor IMDC/MSKCC risk who require systemic therapy. Metastasectomy can be contemplated in selected subjects with a limited number of metastases or long metachronous disease-free interval. For the population of patients with metastatic ccRCC as a whole, the combination of pembrolizumab–axitinib, nivolumab–cabozantinib, or pembrolizumab–lenvatinib can be considered as the first option based on the benefit obtained in OS versus sunitinib. In cases that have an intermediate IMDC and poor prognosis, the combination of ipilimumab and nivolumab has demonstrated superior OS compared to sunitinib. As for individuals with advanced RCC previously treated with one or two antiangiogenic tyrosine-kinase inhibitors, nivolumab and cabozantinib are the options of choice. When there is progression following initial immunotherapy-based treatment, we recommend treatment with an antiangiogenic tyrosine-kinase inhibitor. While no clear sequence can be advocated, medical oncologists and patients should be aware of the recent advances and new strategies that improve survival and quality of life in the setting of metastatic RC.